Roivant Sciences Ltd. shares ROIV fell 3% premarket on Monday after the company said the experimental treatment brepocitinib failed to meet its main goal in a trial involving patients with moderate to severe lupus. Due to the high placebo response rate seen in the trial, “it was not possible to truly assess the impact of the drug, or to establish sufficient differentiation from other therapies in lupus patients,” Roivant CEO Matt Gline said in a statement. Roivant will not pursue further development of brepocitinib in systemic lupus erythematosus, the most common type of lupus, Gline sad, but is still enthusiastic about…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Already a subscriber?
Log In
